The General Hospital Corporation;UTI Limited Partnership
发明人:
Santamaria, Pere,Moore, Anna
申请号:
AU2018203257
公开号:
AU2018203257B2
申请日:
2018.05.10
申请国别(地区):
AU
年份:
2019
代理人:
摘要:
#$%^&*AU2018203257B220191107.pdf#####Abstract The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.